Caris Life Sciences released interim validation data from its Achieve 1 study supporting the launch of Caris Detect, a multicancer early detection (MCED) blood assay. In diagnosed cohorts the assay showed sensitivity rising with stage (about 57% stage I to 99% stage IV) and specificity of ~95% in undiagnosed participants; an independent blinded validation cohort remains pending. Caris said it plans to launch Caris Detect in Q2 and continues processing additional cohorts (Achieve 2) to refine sensitivity across cancer types. The company highlighted a high specificity signal in asymptomatic screening subsets but acknowledged the need for blinded validation results targeted for Q1. Positive validation could accelerate competition in the MCED market and affect screening strategies and payer discussions; Caris’ next steps will focus on independent validation, regulatory positioning and reimbursement planning.